The respiratory team has grown Brovana 1 million dollars and will be significantly under its $315 million forecast for the year. Lonhola is doing $8 million in sales and that has everyone selling it except the Institutional team. Which is doing almost as good in sales with 25 reps selling Novartis hand-me downs. The pipeline has zero respiratory interest or developments after Lonhola, Brovana is flat, and it’s LOE is up in 18 months. Lonhola is going to get it’s ass handed to it now with a superior product to compete against. This is looking more like a respiratory franchise sale of Lonhola to smaller company that needs a niched $50-70 million dollar drug. $8 million in sales and most of it is in wholesalers & inventory for a year of work??? That doesn’t pay all of us and a LTC team long-term. Enough to get a smaller company to buy it. Good luck to everyone.